Department of Health and Social Care (DHSC) has implemented a process to roll over certain concessionary prices to the following month.
From May 2023, the roll over process will apply to any products where agreement is reached on the final prices granted by DHSC for any price concession requests
submitted late in the month (on or after the 23rd of the month) by Community Pharmacy England.
Community Pharmacy England said: "As part of the Year 4 & 5 funding settlement for community pharmacy, it was agreed that an urgent review of the price concession
setting system would take place."
It has been working with DHSC to determine improvements to the price concession system.
Community Pharmacy England said: "Pharmacy owners (members) will be able to see the lines that have rolled over on our price concessions page here. Please note
any rolled over prices can be adjusted upwards if we receive reports from our members to indicate suppliers' selling prices have increased. The review can be
requested at any point during the month."
The price concession for Atorvastatin 80mg has been increased to £3.91 from the previously set £3.45 for prescriptions dispensed in July, the Community Pharmacy
England has said. The Department of Health and Social Care additionally introduced a concession price of £3.38 for Atorvastatin 20mg.
"In July, our Dispensing and Supply Team experienced an unusually high influx of reports from pharmacies struggling to acquire Atorvastatin 80mg tablets at the
listed Drug Tariff price," said CPE.
CPE requested a price concession early in the month. However, after extended discussions, an agreement on the price wasn't reached. Consequently, on July 31st, the
DHSC imposed a concession of £3.45.
Addressing enduring pharmacy concerns over the pricing, CPE intensified advocacy with DHSC. This endeavour resulted in the revision of the Atorvastatin 80mg tablet
concession price to £3.91 for prescriptions submitted and dispensed in July.
According to CPE, this adjusted price sufficiently covers costs as reported by the majority of pharmacy owners.
However, DHSC has refrained from modifying concessionary prices for the other two requested lines by CPE. DHSC communicated that their team's data collection for
July, employing real-time sales and volume data, was incongruent with the adjustment of these prices, CPE further said.
Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England
regarding medicine pricing issues reported by pharmacy owners (its members).
A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.
Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online
feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.
The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
The Pharmaceutical Services Negotiating Committee (PSNC) has rejected Department of Health and Social Care (DHSC) and NHS England's proposal on price
concessions reform and relief measures to ease pressure on pharmacies.
The Committee called the proposal 'insufficient' to meet the sector's needs considering the impact of the current crisis, reflecting on the economic pressures
that accelerated through the autumn and winter.
The Ministers and other decision-makers have shown their interest in the potential role of community pharmacy, particularly in using a Pharmacy First approach
and making use of PGDs and the skills of independent prescribers.
But the Committee had made clear to them that without new money this is all a pipedream. "We need an urgent injection of funds into the sector, otherwise we will
continue to see a degradation of services and eventual collapse of the network. The Committee is clear that there is no further place for warm words while pharmacy
collapses," said PSNC.
The Committee reflected that the 5-year CPCF agreement had been based on working together to create the capacity and context necessary to deliver the shift towards
greater service delivery. Not only has that capacity-release not happened due to slow progress by Government, but pharmacies have also been burdened with these
additional, and insurmountable, challenges.
The Department of Health and Social Care (DHSC) has redetermined the December 2023 concessionary prices for four medicines following requests made by
Community Pharmacy England (CPE) on behalf of community pharmacy owners.
For Ezetimibe 10mg tablets (pack size 28), the price has been fixed at £17.78, up from £9.44.
Other drugs included in the list are Aripiprazole 5mg (£8.52), Digoxin 125microgram (£3.70) and Digoxin 250micrgram (£3.70) tablets.
Contractors would be reimbursed at the new prices only for prescriptions submitted for payment for the dispensing month of December 2023.
CPE said they are still working with DHSC to agree price concessions for January.
Check the final the December 2023 price concessionary here.
Additionally, DHSC on Friday confirmed that there's now sufficient stock of Clarithromycin 125mg/5ml oral suspension to meet normal demand, and the Serious
Shortage Protocol (SSP), SSP053 for the antibiotic expires on 12 January 2024.
The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor.
Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total
number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022.
PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly
been concerned about the lack of certainty around the final reimbursement prices for these medicines.
It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are
getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."
The NHS Business Services Authority (NHSBSA) has published the Drug Tariff Category M price list for July which reflects an increase in reimbursement
level of approximately £5m per quarter.
An adjustment of -£23.8m was announced, in light of the results of the margin survey (latest result up until end of December 2022), and the phasing down of the
additional £100m agreed across years 4 and 5 as part of the Community Pharmacy Contractual Framework and uplifts for underlying market prices
(between January - March 2023).
Community Pharmacy England has agreed the adjustments based on the analysis of margin delivery and on current projections for 2023/24.
It said: "The objectives are to ensure full delivery of agreed margin and smooth delivery as much as possible. As always, the impact on individual pharmacies
will vary depending on dispensing mix."
Department of Health and Social Care (DHSC) has increased the rate of discount deduction for generics from 17.52 per cent to 20 per cent.
The Drug Tariff for April 2023 will contain changes to the discount deduction arrangements for pharmacy contractors, which will include- all concession lines to be
considered as Group Items for Discount Not Deducted i.e. DND or zero discount (ZD) items; and rate of discount deduction for generics to increase from 17.52% to 20%
The Pharmaceutical Services Negotiating Committee (PSNC) and DHSC agreed on the changes for all concession lines to be considered as Group Items for Discount Not
Deducted. Therefore from 1 April 2023, a new category will be introduced into Part II of the Drug Tariff 'Drugs for which discount is not deducted'.
However, the committee had rejected the changes in the rate of discount deduction for generics. It said, "Following pressure from NHS England, Ministers have now
chosen to impose changes to the previously agreed discount deduction arrangements, which come into effect from 1 April, and will be kept under review."